Innogen  ·  Publications  ·  Briefings
Appropriate Governance of the Life Sciences (08)
Smarter Regulation of Drug Development: FDA Orphan Products and FastTrack Programmes

Advances in biomedical sciences are predicted to have enormous impact on the prevention, diagnosis, treatment and cure of disease and disability, for example pharmacogenomics, proteomics, nanotechnologies, micro-arrays, biomarkers, bio-informatics, synthetic biology, and tissue engineering. On the other hand, the R&D process is increasingly costly, unpredictable and inefficient, so that these advances will not automatically translate into improvements in health care.